A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics

L Forchette, W Sebastian, T Liu - Current medical science, 2021 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of
the coronavirus disease 2019 (COVID-19), has caused more than 179 million infections and …

A global picture: therapeutic perspectives for COVID-19

VP Chavda, C Kapadia, S Soni, R Prajapati… - …, 2022 - Taylor & Francis
The COVID-19 pandemic is a lethal virus outbreak by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), which has severely affected human lives and the global …

[HTML][HTML] Therapeutics for COVID-19 and post COVID-19 complications: An update

D Basu, VP Chavda, AA Mehta - Current Research in Pharmacology and …, 2022 - Elsevier
Since its inception in late December 2020 in China, novel coronavirus has affected the
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …

Therapeutic monoclonal antibodies for COVID-19 management: an update

VP Chavda, R Prajapati, D Lathigara… - Expert opinion on …, 2022 - Taylor & Francis
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
affected more than 529 million people, and today the world is facing different mutant strains …

Evolution of SARS-CoV-2 variants: implications on immune escape, vaccination, therapeutic and diagnostic strategies

NZ Zabidi, HL Liew, IA Farouk, A Puniyamurti, AJW Yip… - Viruses, 2023 - mdpi.com
The COVID-19 pandemic caused by SARS-CoV-2 is associated with a lower fatality rate
than its SARS and MERS counterparts. However, the rapid evolution of SARS-CoV-2 has …

Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial

H Bian, ZH Zheng, D Wei, A Wen, Z Zhang… - Signal transduction and …, 2021 - nature.com
Abstracts Recent evidence suggests that CD147 serves as a novel receptor for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Blocking CD147 via anti …

COVID-19 vaccination scenarios: a cost-effectiveness analysis for Turkey

A Hagens, AÇ İnkaya, K Yildirak, M Sancar… - Vaccines, 2021 - mdpi.com
As of March 2021, COVID-19 has claimed the lives of more than 2.7 million people
worldwide. Vaccination has started in most countries around the world. In this study, we …

Association of HLA gene polymorphism with susceptibility, severity, and mortality of COVID‐19: a systematic review

P Deb, K Zannat, S Talukder, AH Bhuiyan, MSA Jilani… - Hla, 2022 - Wiley Online Library
HLA is crucial for appropriate immune responses in several viral infections, as well as in
severe acute respiratory syndrome coronavirus‐2 (SARS CoV‐2). The unpredictable nature …

Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis

J Deng, K Heybati, HB Ramaraju, F Zhou, D Rayner… - Infection, 2023 - Springer
Purpose To assess and compare the relative efficacy and safety of anti-SARS-CoV-2
antibody regimens for COVID-19. Methods This systematic review and random-effects …

[HTML][HTML] Persistent SARS-CoV-2 nucleocapsid protein presence in the intestinal epithelium of a pediatric patient 3 months after acute infection

D Arostegui, K Castro, S Schwarz, K Vaidy… - Jpgn …, 2022 - journals.lww.com
In addition to the severe impact of acute respiratory disease during the SARS-CoV-2
pandemic, the issue of “Long COVID” illness has impacted large numbers of patients …